Elsevier BV Showcase

Citation metrics are widely used and misused. We have created a publicly available database of top-cited scientists that provides standardized information on citations, h-index, co-authorship adjusted hm-index, citations to papers in different authorship positions and a composite indicator (c-score). Separate data are shown for career-long and single recent year impact. Metrics with and without self-citations, ratio of citations to citing papers, retracted papers (based on Retraction Watch database) and citations to/from retracted papers are also shown to facilitate mapping of potential research integrity issues. Scientists are classified into 20 scientific fields and 174 sub-fields (Science-Metrix classification). Field- and subfield-specific percentiles are also provided for all scientists with at least 5 papers. Career-long data are updated to end-of-2025 and single recent year data pertain to citations received during calendar year 2025. The selection is based on the top 100,000 scientists by c-score (with and without self-citations) or a percentile rank of 2% or above in the sub-field. This version (9) is based on the August 1, 2026 snapshot from Scopus, updated to end of citation year 2025. Calculations were performed using all Scopus author profiles as of August 1, 2026. The c-score focuses on impact (citations) rather than productivity (number of publications) and it also incorporates information on co-authorship and author positions (single, first, last author). We make the data publicly available to facilitate transparency and research, but some websites that disseminate the data may interpret them in misleading ways, e.g. as absolute evidence of excellence. If an author is not on the list, it is simply because the composite indicator value was not high enough to appear on the list. It does not mean that the author does not do good work. PLEASE ALSO NOTE THAT THE DATABASE HAS BEEN PUBLISHED IN AN ARCHIVAL FORM AND WILL NOT BE CHANGED. The published version reflects Scopus author profiles at the time of calculation. We advise authors to ensure that their Scopus profiles are accurate. REQUESTS FOR CORRECTIONS OF SCOPUS DATA (INCLUDING CORRECTIONS IN AFFILIATIONS) SHOULD NOT BE SENT TO US. Instead, please sign in using the Scopus Author Feedback Wizard to submit such requests so that correct data can be used in future annual updates of the citation indicator databases. For any additional questions, see attached file on FREQUENTLY ASKED QUESTIONS. All citation metrics have limitations and their use should be tempered and judicious, e.g. see the Leiden manifesto: https://www.nature.com/articles/520429a

This is the supplementary data for the article "Science-wide mapping and ranking of institutions based on affiliated authors". The data provided here is based on the August 2025 data-update for "Updated science-wide author databases of standardized citation indicators": https://elsevier.digitalcommonsdata.com/drafts/btchxktzyw/8.

This repository includes the base notebooks used to prepare the patent and trademark data for SEI 2024. This covers the uploading of the PatentsView database, its curation, and the preparation of patent and trademark indicators across all the mapping classifications.

-----> Human Disease Author Aid Collection combines information about human diseases in standardized, easy-to-navigate overview templates and tables. It includes clinical, molecular, and pharmacological data from several Elsevier's and public sources. Tables are planned to be updated quarterly. -----> Author Aid Templates can be a helpful guide for authors, researchers, clinicians, and students, especially those interested in rare diseases, because it highlights updates and findings from several sources on one page. -----> Each disease template overview includes 6 sections: Terminology; Epidemiology/Demographics; Clinical presentation/Diagnosis; Etiology/Pathology (genetics, biomarkers, pathways); Treatment/Follow-Up; Case studies. Each subset of data is linked to a list of publications with relevant citations. -----> Cancers (Human Disease Author Aid Collection, Part 4) In the current part, selected Gynecological and Brain cancers were chosen based on their prevalence, and data availability. Part 3 includes A) Templates for: Endometrial cancer Ovarian Cancer Сervical cancer Gestational trophoblastic disease Сhoriocarcinoma B) Automatically collected information about 8 Brain Cancers. ----> PLEASE download files to read them and open the links!

Author information for: Hyperprolific physics authors by year 2000-2022 inclusive. Author needs to have 73 or more publications in a year to qualify and their main field from 2000 to 2022 is Physics & Astronomy Hyperprolific non-physics authors by year 2000-2022 inclusive. Author needs to have 73 or more publications in a year to qualify and their main field from 2000 to 2022 must not be Physics & Astronomy Almost Hyperprolific physics authors by year 2000-2022 inclusive. Author needs to have between 61 and 72 publications in a year to qualify and their main field from 2000 to 2022 is Physics & Astronomy Almost Hyperprolific non-physics authors by year 2000-2022 inclusive. Author needs to have between 61 and 72 publications in a year to qualify and their main field from 2000 to 2022 must not be Physics & Astronomy Data: year - The year of publication of the articles, reviews, and conference proceedings analyzed in this study author_field - The primary field assigned to the author based upon publications and share of publications in the field field - The ScienceMetrix field classification of the journal the publication appears in Pubs_in_field_year - Total number of publications by the author in the given year in the given field Pubs_year_total - Total number of publications by the author in the given year Pubs_in_field_2000_2022 - Total number of publications by the author in the period 2000 to 2022 in the given field, Pubs_2000_2022_total - Total number of publications by the author in the period 2000 to 2022 rank - The author's rank, within their SM subfield, based on citation count rank (ns) - The author's rank, within their SM subfield, based on citation count with self citations excluded sm-subfield-1 - The author's SM subfield rank sm-subfield-1 - The author's rank, within their SM subfield, based upon their citation score rank sm-subfield-1 (ns) - The author's rank, within their SM subfield, based upon their citation score excluding self citations sm-subfield-1 count - The number of authors in the SM subfield Subfield_Percentile - 100 * rank/count Subfield_Percentile_ns - 100 * rank (ns)/count author_name - Author's name from their Scopus Author Profile hidx - The author's career H-Index affil_name - The name of the author's most recent affiliation cntry - The country of the author's most recent affiliation Total_Pubs - The number of articles, reviews, and conference proceedings from the affiliation in the period Pubs_with_more_than_100_authors - The number of articles, reviews, and conference proceedings from the affiliation in the period with more than 100 authors Pubs_with_more_than_500_authors - The number of articles, reviews, and conference proceedings from the affiliation in the period with more than 500 authors Pubs_with_more_than_1000_authors - The number of articles, reviews, and conference proceedings from the affiliation in the period with more than 1000 authors

-----> Human Disease Author Aid Collection combines information about rare and common diseases in standardized, easy-to-navigate overview templates and tables. It includes clinical, molecular, and pharmacological data from several Elsevier's and public sources. Tables are planned to be updated quarterly. -----> Author Aid Templates can be a helpful guide for authors, researchers, clinicians, and students, especially those interested in rare diseases, because it highlights updates and findings from several sources on one page. -----> Each disease template overview includes 6 sections: Terminology; Epidemiology/Demographics; Clinical presentation/Diagnosis; Etiology/Pathology (genetics, biomarkers, pathways); Treatment/Follow-Up; Case studies. Each subset of data is linked to a list of publications with relevant citations. -----> Monogenic Rare Diseases (Human Disease Author Aid Collection, Part 2) In the current part, monogenic rare diseases were chosen based on their classification, prevalence, and degree of data availability. By "monogenic" we mean diseases that are caused by one or few known mutations. We considered worldwide point prevalence between <1/10 or 100 thousand (worldwide) as a criterion for filtering most significant rare diseases. Contents A) Curated templates about monogenic rare diseases: • Achondroplasia • Facioscapulohumeral dystrophy • Familial Mediterranean fever • Hereditary breast and ovarian cancer syndrome • Huntington disease • Congenital hypothyroidism • Rett syndrome • Usher syndrome • Wilson’s disease • Wiskott-Aldrich syndrome B) Automatically collected information about additional 21 Rare monogenic diseases. -----> PLEASE download files to read them and open the links!

Underlying bibliometric data for the manuscript Mobilizing Interdisciplinarity: Insights from an Institution-Wide Research Strategy

Chinese Medicine has a rich history that plays an important role in contemporary healthcare. This report presents a comprehensive bibliometric analysis of research on Chinese Medicine from 2014 to 2023, highlighting its development, shifting research focuses, impact on other fields, and key contributors. It outlines the Chinese Medicine research landscape, showcasing how this ancient medical practice evolves and thrives with modern science. More information at https://cm-evaluation.scm.hkbu.edu.hk/

This data describes Newton's third law of motion which states that "in every action there is an opposite or equal reaction".

The global research community is making progress, albeit slowly, towards the full and equal participation of women. This webinar recording presents highlights from a major new data-driven analysis of gender diversity in research. Building on prior work by Elsevier, this analysis draws on Scopus data stretching back more than two decades to assess the representation of women in research and changes over time, in a global context and for 18 countries. Beyond examining men’s and women’s research participation and research footprint, new insights will be presented on gender participation across career stages, in areas such as interdisciplinarity and multidisciplinarity, open access publication, SDGs, mentorship contribution, and alternative metrics, to paint a fuller picture of the state of gender equity in the global research ecosystem and inform evidence-based policy and interventions. You will learn about: The benefits of adopting a longer time frame for academic evaluation and assessments; The impact of hiring and retaining senior women researchers; The importance of including societal impact metrics in evaluations or career assessments, and more. The webinar can be visioned at : https://researcheracademy.elsevier.com/communicating-research/inclusion-diversity-researchers/progress-toward-gender-equality-research